Inhibition of Neurotoxic Secretory Phospholipases A<sub>2</sub> Enzymatic, Edematogenic, and Myotoxic Activities by Harpalycin 2, an Isoflavone Isolated from <i>Harpalyce brasiliana</i> Benth

<table>Effect of harpalycin 2 (Har2) on edema formation after a single subplantar injection of sPLA<sub>2</sub> (25 <i>μ</i>g/paw) from (a) <i>Bothrops pirajai</i> (PrTX-III), (b) <i>Crotalus durissus terrificus</i> (Cdt F15), (c) <i>Apis mellifera</i> (Apis), and (d) <i>Naja naja</i> (Naja) venom expressed as the increase in paw volume (<i>μ</i>L). Native sPLA<sub>2</sub> edematogenic activity is represented by circles whereas harpalycin 2 treated sPLA<sub>2</sub> edematogenic activity is showed as squares. Data expressed as mean ± S.E.M. and analyzed by ANOVA followed by Dunnett’s test, with *<i>P</i> set at 0.05.</table>

Evidence-Based Complementary and Alternative Medicine

fig3

Figure 3

Figure 3: Inhibition of Neurotoxic Secretory Phospholipases A<sub>2</sub> Enzymatic, Edematogenic, and Myotoxic Activities by Harpalycin 2, an Isoflavone Isolated from <i>Harpalyce brasiliana</i> Benth 

Figure 3 | Inhibition of Neurotoxic Secretory Phospholipases A2 Enzymatic, Edematogenic, and Myotoxic Activities by Harpalycin 2, an Isoflavone Isolated from Harpalyce brasiliana Benth 